# Quality Gate Results

**Session:** 2026-03-18-targeted-001
**Fields:** Ferroptosis biology x Bacterial quorum sensing
**Validator:** Quality Gate Agent (Opus 4.6)
**Date:** 2026-03-18
**Rubric version:** 10-point (v5.4 with per-claim grounding verification)

---

## Critical Context

The 2025 Nature Communications paper (Li et al., Nov 2025) demonstrates that PQS induces macrophage ferroptosis via a CNMT-TFR1 methylation pathway. This means the QS-to-ferroptosis direction is no longer fully disjoint. Any hypothesis in this direction must offer a mechanistically distinct pathway from PQS-CNMT-TFR1. Additionally, P. aeruginosa pLoxA-mediated "theft-ferroptosis" (Dar et al., JCI 2018) is established for epithelial cells. The bar for novelty in QS-to-ferroptosis is therefore significantly raised.

**Literature context was parametric-only** (literature scout failed). All factual claims require independent web verification.

---

## Hypothesis 1: C2-3 (Score 7.90)
### "Pyocyanin-Initiated Mitochondrial Lipid Peroxidation Radical Chain Reactions Induce DHODH-Pathway-Specific Ferroptosis"

**Connection:** P. aeruginosa QS-regulated pyocyanin -> Mitochondrial redox cycling -> Superoxide/Fenton radical chain PUFA-PE oxidation -> DHODH pathway overwhelmed -> Compartment-specific ferroptosis

### Web Searches Performed

1. **Novelty: "pyocyanin ferroptosis DHODH mitochondrial lipid peroxidation"** -- No papers found connecting pyocyanin to ferroptosis. NOVEL as of March 2026.
2. **Novelty: "pyocyanin ferroptosis airway epithelial cells 2024 2025 2026"** -- No direct papers. Ferroptosis research in airway cells focuses on PM2.5, STAT6, not pyocyanin. NOVEL.
3. **Novelty: site:semanticscholar.org "pyocyanin ferroptosis"** -- No co-occurrence. NOVEL.
4. **Counter-evidence: "pyocyanin ferroptosis contradicted OR failed"** -- CRITICAL FINDING: A 2016 study (Muller et al., PMC5139071) on NRK-52E renal tubular epithelial cells found that "inhibitors of programmed necrotic pathways including ferroptosis could not protect cells" from pyocyanin. Pyocyanin-induced death was classified as "paraptosis-like." However, this was in renal cells, not airway epithelial cells, and at unspecified concentrations. Cell type matters significantly for ferroptosis susceptibility.
5. **Mechanism: "pyocyanin CoQ10 mitochondria redox cycling superoxide"** -- VERIFIED: Pyocyanin undergoes mitochondrial redox cycling (Usher et al., 2002, PMID:12414438). Pyocyanin reduces NADPH and generates superoxide. Confocal/EM studies confirm mitochondrial localization.
6. **Mechanism: "pyocyanin redox cycling depletes GSH NAD lung epithelial"** -- VERIFIED: O'Malley et al. (2004, Am J Physiol Lung) showed pyocyanin depletes GSH by up to 50% in human bronchial epithelial cells, directly oxidizing GSH to GSSG.
7. **Mechanism: "DHODH CoQ10H2 ferroptosis mitochondrial defense Mao 2021"** -- VERIFIED: Mao et al. (2021, Nature) demonstrated DHODH reduces CoQ10 to CoQ10H2 as a mitochondrial ferroptosis defense. DHODH inhibition + GPX4 loss = mitochondrial ferroptosis.
8. **Key claim: "pyocyanin accepts electrons from ubiquinol"** -- VERIFIED: Guaras et al. (2021, Nat Commun, PMC8032734) showed pyocyanin's standard electrochemical potential is close to ubiquinol/ubiquinone couple. Pyocyanin accepts electrons from decylubiquinol. This directly supports the CoQ10H2 depletion mechanism.
9. **Mechanism: "pyocyanin concentration sputum cystic fibrosis micromolar"** -- VERIFIED: Pyocyanin reaches up to 100 micromolar in CF sputum. Therapeutic (non-toxic) range is sub-micromolar to 3 micromolar; 50-100 micromolar is toxic. CF-relevant concentrations are in the toxic range.
10. **Mechanism: "pyocyanin QS-regulated phzA"** -- VERIFIED: phz1 and phz2 operons are QS-regulated via LasR/RhlR and PQS/PqsE.
11. **Counter-evidence: "pyocyanin cell death necrosis apoptosis"** -- Pyocyanin induces apoptosis in neutrophils and necrosis at higher concentrations. No one has specifically tested ferrostatin rescue in lung epithelial cells.

### Per-Claim Grounding Verification

| Claim | Type | Status | Evidence |
|-------|------|--------|----------|
| Pyocyanin is QS-regulated | Descriptive | VERIFIED | phz operons under LasR/RhlR/PQS control (Dietrich et al. 2006 Mol Micro) |
| Pyocyanin undergoes mitochondrial redox cycling | Mechanistic | VERIFIED | Usher et al. 2002 (PMID:12414438) confocal/EM evidence |
| Redox cycling generates superoxide | Mechanistic | VERIFIED | Multiple studies; pyocyanin + NADPH -> superoxide + H2O2 |
| Pyocyanin depletes GSH in airway epithelial cells | Mechanistic | VERIFIED | O'Malley et al. 2004 Am J Physiol Lung (up to 50% depletion) |
| Pyocyanin electrochemical potential close to ubiquinol | Mechanistic | VERIFIED | Guaras et al. 2021 Nat Commun |
| Pyocyanin can accept electrons from ubiquinol | Mechanistic | VERIFIED | Guaras et al. 2021 demonstrated this directly |
| CoQ10H2 depletion would disable DHODH defense | Mechanistic | SUPPORTED | Logical consequence of Mao 2021 (DHODH needs CoQ10 as substrate) -- not directly tested with pyocyanin |
| DHODH is a mitochondrial ferroptosis defense | Mechanistic | VERIFIED | Mao et al. 2021 Nature |
| This would produce DHODH-pathway-specific ferroptosis | Predictive | SPECULATIVE | Pyocyanin's pleiotropic effects (GSH depletion, NADPH depletion) would attack all three axes simultaneously, not just DHODH |
| Pyocyanin concentrations in CF are sufficient | Contextual | VERIFIED | Up to 100 micromolar in CF sputum |
| No prior pyocyanin-ferroptosis publication | Novelty | VERIFIED | No papers found in multiple searches as of March 2026 |

**Groundedness: 8/11 claims VERIFIED, 1 SUPPORTED, 1 SPECULATIVE, 1 VERIFIED (novelty)**
**Groundedness score: 0.82 (9 verifiable / 11 total)**

### 10-Point Rubric

| Check | PASS/FAIL | Evidence |
|-------|-----------|----------|
| 1. A->B->C structure | PASS | Clear: QS-regulated pyocyanin -> mitochondrial redox cycling/CoQ10H2 depletion -> DHODH pathway overwhelm -> ferroptosis |
| 2. Mechanism specificity | PASS | Names specific pathway (DHODH-CoQ10H2), identifies redox cycling mechanism, specifies mitochondrial compartment. However, the "DHODH-pathway-specific" claim is likely oversimplified since pyocyanin also depletes GSH (attacking GPX4 axis) and NADPH (attacking FSP1 axis) |
| 3. Falsifiable prediction | PASS | Testable: brequinar + pyocyanin should show synergistic ferroptosis in GPX4-high cells; ferrostatin-1 should rescue pyocyanin-induced death in airway epithelia; DHODH overexpression should partially protect |
| 4. Counter-evidence quality | PASS | Genuine risks identified: pleiotropic effects masking ferroptosis, NRK-52E study showing ferroptosis inhibitors failed (though different cell type), borderline triviality concern |
| 5. Test protocol actionable | PASS | C11-BODIPY in bronchial epithelial cells +/- pyocyanin +/- ferrostatin-1; brequinar synergy assay; DHODH knockdown; MitoPerOx for compartment specificity. All standard techniques. |
| 6. Confidence calibration | PASS | Revised confidence 5/10 is appropriate. Strong mechanistic logic with verified components, but no direct experimental connection yet. The compartment-specificity claim elevates uncertainty. Honest acknowledgment of trivially-deducible concern. |
| 7. Novelty (web-verified) | PASS | No pyocyanin-ferroptosis papers found across multiple searches. Distinct from PQS-CNMT-TFR1 (different molecule, different mechanism, different compartment). Distinct from pLoxA theft-ferroptosis (different mechanism). |
| 8. Groundedness | PASS | 0.82 groundedness score. All individual mechanistic components verified in literature. The gap is the COMBINATION, which is the hypothesis's contribution. |
| 9. Language precision | PASS | Specialist-appropriate language: names DHODH, CoQ10H2, PUFA-PE, phz operons. Could be more precise about which PUFA-PE species are targeted in mitochondrial membranes (cardiolipin-associated PE vs other species). |
| 10. Per-claim grounding | PASS (with caveat) | See table above. 9/11 claims verified or supported. The "DHODH-pathway-specific" framing is the weakest claim -- pyocyanin attacks all three ferroptosis defense axes, so compartment specificity is questionable. Revise to "pyocyanin-induced ferroptosis with prominent mitochondrial component." |

### Confidence Adjustment
- Original: 7 (Generator) -> 5 (Critic)
- Quality Gate assessment: **5/10**
- Rationale: All mechanistic components are individually verified, but (a) the NRK-52E counter-evidence raises concern that pyocyanin may cause death via non-ferroptotic mechanisms, (b) the DHODH-specific framing is likely wrong since pyocyanin attacks all three axes, (c) no one has yet shown that ferrostatin rescues pyocyanin-induced epithelial death. The hypothesis is reasonable but the "DHODH-pathway-specific" claim adds unjustified precision.

### VERDICT: CONDITIONAL PASS

**Reason:** All individual mechanistic components are web-verified and the connection is genuinely novel (no published pyocyanin-ferroptosis link). The hypothesis correctly identifies that pyocyanin's mitochondrial redox cycling could overwhelm the DHODH-CoQ10H2 defense. However, the "DHODH-pathway-specific" framing should be softened to acknowledge pyocyanin's pleiotropic attack on all ferroptosis defense systems. The counter-evidence from NRK-52E cells (paraptosis, not ferroptosis) is a genuine concern but may be tissue-specific. Passes because the core connection (QS-regulated pyocyanin -> mitochondrial lipid peroxidation -> ferroptosis) has strong mechanistic grounding and the falsifiable prediction (ferrostatin rescue) would definitively resolve the outstanding question.

**Revised title:** "Pyocyanin Mitochondrial Redox Cycling Initiates Ferroptosis in Airway Epithelia via CoQ10H2 Depletion and DHODH Pathway Compromise"

---

## Hypothesis 2: C2-7 (Score 7.10)
### "Fur-Mediated PQS Functional Switch Under Ferroptotic Iron Excess"

**Connection:** Ferroptotic iron/heme release -> Fur activation -> Siderophore repression + heme uptake maintenance -> PQS decoupled from iron scavenging -> PQS repurposed as ferroptosis amplifier (via CNMT-TFR1) -> Positive feedback loop

### Web Searches Performed

1. **Novelty: "Fur PQS ferroptosis iron Pseudomonas"** (Semantic Scholar) -- No papers connecting Fur-mediated regulatory changes to ferroptosis feedback. NOVEL.
2. **Critical mechanism: "Fur iron replete PQS Pseudomonas production"** -- CRITICAL FINDING: Oglesby-Sherrouse & Vasil (2008, JBC, PMC2414296) showed iron INCREASES PQS production in WT P. aeruginosa, via kynurenine pathway supplying anthranilate. However, PrrF-antR pathway also increases anthranilate degradation under iron excess. NET EFFECT: iron increases PQS in WT (kynurenine pathway compensates), and PQS levels jumped >6-fold in PrrF mutant under iron supplementation.
3. **Mechanism: "Pseudomonas aeruginosa iron excess PQS decrease PrrF antR anthranilate"** -- Complex picture. Iron activates both anthranilate biosynthesis (kynurenine) and degradation (antABC). Net effect in WT: PQS INCREASES under iron excess. This SUPPORTS the hypothesis's PQS amplification claim.
4. **Counter-evidence: "Pseudomonas iron excess Fur repress virulence"** -- Iron-virulence relationship is context-dependent. Fur represses some virulence genes (siderophores, ExoA) but PQS production is maintained or increased under iron excess. Not a simple repression model.
5. **Mechanism: PQS-CNMT-TFR1 ferroptosis** -- VERIFIED: Li et al. 2025 Nature Communications. PQS induces macrophage ferroptosis via CNMT-mediated TFR1 His35 methylation, increasing iron uptake.
6. **Mechanism: "Pseudomonas heme uptake iron excess Fur has operon"** -- VERIFIED: P. aeruginosa has phu and has heme uptake systems. Fur represses iron acquisition genes under iron-replete conditions but the relationship between Fur, heme uptake specifically, and iron-replete conditions is nuanced.
7. **Counter-evidence: PrrF-antR reduces PQS under iron excess** -- PARTIALLY CONTRADICTED: While PrrF loss does derepress antR/anthranilate degradation, the kynurenine pathway compensates. The critic's claim that "PrrF-antR pathway reduces PQS under iron excess" appears to be wrong for WT cells based on Oglesby-Sherrouse 2008 data showing PQS INCREASES.

### Per-Claim Grounding Verification

| Claim | Type | Status | Evidence |
|-------|------|--------|----------|
| Ferroptotic cells release iron/heme | Mechanistic | VERIFIED | Established ferroptosis mechanism; labile iron pool expansion drives ferroptosis |
| Fur activates under iron excess | Mechanistic | VERIFIED | Canonical Fur mechanism (Fe2+-Fur represses iron acquisition genes) |
| Fur represses siderophore genes | Mechanistic | VERIFIED | Fur represses PvdS, pyoverdine, pyochelin genes |
| Iron excess increases PQS production | Mechanistic | VERIFIED | Oglesby-Sherrouse 2008 JBC: iron supplementation increases PQS in WT via kynurenine pathway |
| PQS "decoupled" from iron scavenging | Interpretive | SPECULATIVE | This framing is novel. PQS has multiple functions (QS signal, iron chelator, OMV biogenesis). Under iron excess, iron chelation function becomes less critical, but PQS continues to be produced. "Functional switch" is an interpretive claim, not established. |
| PQS induces ferroptosis via CNMT-TFR1 | Mechanistic | VERIFIED | Li et al. 2025 Nature Communications |
| Positive feedback loop exists | Predictive | SPECULATIVE | Requires ferroptotic iron release -> sustained PQS production -> more ferroptosis. Temporal dynamics uncertain (host iron sequestration by ferritin/lipocalin may limit window) |
| Heme uptake maintained under iron excess | Mechanistic | PARTIALLY VERIFIED | Has/Phu systems exist but Fur-dependent regulation of heme uptake is complex |

**Groundedness: 5/8 claims VERIFIED, 1 PARTIALLY VERIFIED, 2 SPECULATIVE**
**Groundedness score: 0.69 (5.5 verifiable / 8 total)**

### 10-Point Rubric

| Check | PASS/FAIL | Evidence |
|-------|-----------|----------|
| 1. A->B->C structure | PASS | Ferroptotic iron release -> Fur-mediated transcriptional rewiring (PQS maintained, siderophores repressed) -> PQS amplifies ferroptosis via CNMT-TFR1 |
| 2. Mechanism specificity | PASS | Names Fur, PrrF, kynurenine pathway, PQS-CNMT-TFR1. Specifies regulatory logic. However, the "functional switch" framing adds interpretive overlay that may not correspond to a discrete biological transition. |
| 3. Falsifiable prediction | PASS | Testable: Fur mutant should break the feedback loop; iron chelation (DFO) in co-culture should prevent PQS amplification; CNMT knockout macrophages should be resistant |
| 4. Counter-evidence quality | MARGINAL PASS | Identifies PrrF-antR as counter-argument, but the resolution (kynurenine compensation) is actually supported by published data. Should also discuss: host iron sequestration kinetics, PQS total concentration dynamics, and the fact that PQS-CNMT-TFR1 was demonstrated in macrophages (not epithelia where ferroptosis context matters) |
| 5. Test protocol actionable | PASS | Co-culture assays with Fur/PrrF mutants + macrophages; PQS quantification via LC-MS under iron-supplemented conditions; TFR1 methylation assays |
| 6. Confidence calibration | PASS | 4/10 post-critique is reasonable. The iron-PQS positive correlation is verified but the feedback loop and "functional switch" framing remain speculative. |
| 7. Novelty (web-verified) | MARGINAL PASS | The individual components are all published: (a) iron increases PQS (2008), (b) PQS causes ferroptosis (2025). The NOVEL claim is specifically that this creates a positive feedback loop where ferroptotic iron release feeds PQS production which amplifies ferroptosis. This feedback framing has not been published. However, the connection is close to trivially deducible given the 2025 Nature Comms paper and the 2008 JBC data. A reviewer could argue this is a straightforward prediction from combining two known facts. |
| 8. Groundedness | MARGINAL PASS | 0.69 groundedness. The "functional switch" framing and "decoupling" language overstate what the evidence supports. The positive feedback loop is plausible but unverified. |
| 9. Language precision | PASS | Specialist-appropriate terminology. "Transcriptional rewiring" is slightly overblown for what is a well-characterized Fur regulon response to iron. |
| 10. Per-claim grounding | MARGINAL PASS | See table. Core iron-PQS correlation verified. Feedback loop and functional switch framing remain speculative. The reliance on PQS-CNMT-TFR1 (published Nov 2025) as the downstream effector means the truly novel contribution is narrow: specifically, ferroptotic iron release as a PQS production trigger. |

### Confidence Adjustment
- Original: 6 (Generator) -> 4 (Critic)
- Quality Gate assessment: **4/10**
- Rationale: The core claim (iron excess increases PQS production) is verified by Oglesby-Sherrouse 2008. The downstream PQS-ferroptosis mechanism is verified by Li et al. 2025. But the novel contribution -- the feedback loop -- is narrow and potentially trivially deducible. The "functional switch" framing adds interpretive weight not supported by evidence. Host iron sequestration kinetics may break the feedback loop in vivo.

### VERDICT: FAIL

**Reason:** While all individual components are verified, the hypothesis's core novelty is a feedback loop between ferroptotic iron release and PQS-mediated ferroptosis. Given that (a) iron increases PQS production was published in 2008, (b) PQS induces ferroptosis was published in November 2025, the feedback prediction is close to trivially deducible from combining these two facts. The "functional switch" framing (PQS "decoupled" from iron scavenging, "repurposed" as cytotoxin) adds interpretive language that overstates the evidence. Additionally, the hypothesis does not adequately address host iron sequestration kinetics (ferritin, lipocalin-2) that would likely limit the temporal window for any feedback loop. The margin between "novel connection" and "obvious inference from recent publication" is too narrow for a PASS.

---

## Hypothesis 3: E-H8 (Score 7.00)
### "3-oxo-C12-HSL Induces Host Ferroptosis via System Xc- Competitive Inhibition and GSH Depletion"

**Connection:** P. aeruginosa 3-oxo-C12-HSL -> C12 acyl chain occupies SLC7A11 hydrophobic groove -> blocks cystine import -> GSH depletion -> GPX4 substrate limitation -> ferroptosis

### Web Searches Performed

1. **Novelty: "3-oxo-C12-HSL SLC7A11 system Xc- cystine transport inhibition"** -- No papers found. NOVEL.
2. **Novelty: "3-oxo-C12-HSL ferroptosis host cell death"** -- No direct 3-oxo-C12-HSL-ferroptosis papers. Published work shows 3-oxo-C12-HSL causes apoptosis via mitochondrial pathway (caspase-dependent, T2R14-mediated), NOT ferroptosis. NOVEL but counter-evidence exists.
3. **Mechanism: "erastin SLC7A11 xCT binding pocket structure"** -- VERIFIED: Yan et al. 2022 (Cell Research) solved cryo-EM structure of erastin-bound xCT at 3.4 A. Erastin binds in intracellular vestibule between TM1a/TM6b/TM7. Erastin MW = 547, has chlorophenoxy group interacting with Phe254 and quinazolinol group with Gln191/Phe336.
4. **Mechanism: molecular weight comparison** -- 3-oxo-C12-HSL MW = 297. Erastin MW = 547. 3-oxo-C12-HSL is much smaller. Their structures are completely different (erastin is a piperazine-quinazolinone with chlorophenoxy groups; 3-oxo-C12-HSL is a beta-ketoamide linked to a gamma-butyrolactone with a linear C12 chain).
5. **Counter-evidence: "3-oxo-C12-HSL apoptosis caspase mitochondrial"** -- VERIFIED: Multiple studies show 3-oxo-C12-HSL triggers apoptosis, NOT ferroptosis. Mechanism involves mitochondrial depolarization, cytochrome c release, caspase 3/7 activation. Recent (2024) bioRxiv shows T2R14-MCU pathway mediates apoptosis.
6. **Mechanism: "3-oxo-C12-HSL GSH depletion glutathione epithelial"** -- No direct evidence found for GSH depletion by 3-oxo-C12-HSL. The molecule is known to cause ROS production but GSH depletion is not a documented mechanism.
7. **Mechanism: "SLC7A11 hydrophobic substrate binding groove lipophilic"** -- SLC7A11 has 12 hydrophobic transmembrane domains. The substrate binding site is for amino acids (cystine/glutamate). Erastin binds in the intracellular vestibule, not the substrate translocation path per se. The hypothesis's claim of a "hydrophobic groove" that would accommodate a C12 acyl chain is not supported by the structural data.

### Per-Claim Grounding Verification

| Claim | Type | Status | Evidence |
|-------|------|--------|----------|
| 3-oxo-C12-HSL has a C12 acyl chain | Descriptive | VERIFIED | MW 297, C16H27NO4, dodecanoyl chain |
| 3-oxo-C12-HSL is lipophilic | Descriptive | VERIFIED | Long acyl chain, known membrane interactions |
| SLC7A11 has a "hydrophobic groove" for C12 chain | Structural | NOT VERIFIED | Cryo-EM shows substrate site for amino acids. Erastin binds in intracellular vestibule between TMs but via specific pharmacophore interactions (Phe254, Gln191, Phe336), not via accommodation of a linear aliphatic chain. No evidence for a "hydrophobic groove" that would bind a C12 chain. |
| C12 chain "occupies" SLC7A11 | Mechanistic | SPECULATIVE | No structural or functional evidence. The hypothesis assumes that because erastin (a much larger, structurally dissimilar molecule) inhibits SLC7A11, a linear acyl chain could too. This is not supported. |
| 3-oxo-C12-HSL would block cystine import | Predictive | SPECULATIVE | No evidence. The AHL and cystine have no structural similarity. |
| GSH depletion below GPX4 threshold | Mechanistic | SUPPORTED (general) | GSH depletion -> GPX4 substrate limitation is an established ferroptosis mechanism, but no evidence 3-oxo-C12-HSL causes GSH depletion |
| 3-oxo-C12-HSL concentration sufficient at infection site | Contextual | VERIFIED | 10-100 micromolar range in biofilm/infection contexts |
| 3-oxo-C12-HSL causes host cell death | Descriptive | VERIFIED | Established -- but via apoptosis (caspase/mitochondrial pathway), NOT ferroptosis |

**Groundedness: 4/8 claims VERIFIED, 1 SUPPORTED, 1 NOT VERIFIED (structural claim), 2 SPECULATIVE**
**Groundedness score: 0.56 (4.5 verifiable / 8 total)**

### 10-Point Rubric

| Check | PASS/FAIL | Evidence |
|-------|-----------|----------|
| 1. A->B->C structure | PASS | Clear chain: 3-oxo-C12-HSL -> SLC7A11 inhibition -> GSH depletion -> GPX4 substrate loss -> ferroptosis |
| 2. Mechanism specificity | FAIL | The core structural claim ("C12 acyl chain occupies SLC7A11 hydrophobic groove") is not supported by the cryo-EM structure. Erastin's binding involves specific pharmacophore interactions (aromatic pi-stacking with Phe254, H-bonding with Gln191) that a linear aliphatic chain cannot replicate. The mechanism is structurally implausible as stated. |
| 3. Falsifiable prediction | PASS | Testable: cystine uptake assay +/- 3-oxo-C12-HSL; intracellular GSH measurement; ferrostatin rescue; SLC7A11 overexpression should rescue |
| 4. Counter-evidence quality | FAIL | Does not adequately address that 3-oxo-C12-HSL is established as an APOPTOSIS inducer (caspase-dependent, T2R14-MCU pathway). If 3-oxo-C12-HSL caused ferroptosis, the extensive literature on its cytotoxicity mechanism would have detected it. The absence of any ferroptosis signatures in the many 3-oxo-C12-HSL cell death studies is strong counter-evidence that is not discussed. |
| 5. Test protocol actionable | PASS | Standard assays: C11-BODIPY, GSH measurement, cystine uptake with radiolabeled cystine, SLC7A11 competition binding |
| 6. Confidence calibration | FAIL | Confidence 6 (Generator) is too high for a hypothesis whose core structural claim is unverifiable and whose target molecule is established as an apoptosis inducer. Should be 3/10 at most. |
| 7. Novelty (web-verified) | PASS | No published 3-oxo-C12-HSL-SLC7A11 connection. Novel. |
| 8. Groundedness | FAIL | 0.56 groundedness. The key structural claim (SLC7A11 hydrophobic groove accommodating C12 chain) is fabricated -- no such groove exists in the published cryo-EM structure. This is a parametric hallucination presenting a plausible-sounding but structurally unsupported mechanism. |
| 9. Language precision | MARGINAL PASS | Uses correct protein names. "Hydrophobic groove" is misleading given the actual SLC7A11 structure. |
| 10. Per-claim grounding | FAIL | The structural claim about SLC7A11 binding is not supported by any published evidence. The extensive 3-oxo-C12-HSL cytotoxicity literature consistently identifies apoptosis, not ferroptosis, as the death mechanism. Two critical claims fail grounding. |

### Confidence Adjustment
- Original: 6 (Evolver) -> not re-critiqued as evolved hypothesis
- Quality Gate assessment: **3/10**
- Rationale: The core structural claim is unsupported. While the general principle (GSH depletion -> ferroptosis) is sound, the specific mechanism proposed (C12 chain -> SLC7A11 inhibition) has no structural basis. Additionally, 3-oxo-C12-HSL is well-established as an apoptosis inducer through the T2R14-MCU-mitochondrial pathway. If it also caused ferroptosis via SLC7A11 inhibition, this would have been detected in the many studies of its cytotoxicity.

### VERDICT: FAIL

**Reason:** MECHANISM IMPLAUSIBLE: The core claim that the C12 acyl chain of 3-oxo-C12-HSL occupies an SLC7A11 "hydrophobic groove" is not supported by the published cryo-EM structure of xCT (Yan et al. 2022, Cell Research). Erastin inhibits SLC7A11 via specific pharmacophore interactions (aromatic pi-stacking, H-bonding) that a linear aliphatic chain cannot replicate. Furthermore, 3-oxo-C12-HSL is extensively characterized as an apoptosis inducer (caspase-3/7, T2R14-MCU pathway, cytochrome c release) in multiple cell types -- if it caused ferroptosis via SLC7A11 inhibition, this would have been detected in the literature. The groundedness score of 0.56 with a fabricated structural claim disqualifies this hypothesis.

---

## Summary

| Hypothesis | Score | Verdict | Reason |
|-----------|-------|---------|--------|
| C2-3: Pyocyanin-DHODH Ferroptosis | 7.90 | **CONDITIONAL PASS** | Novel, mechanistically grounded (pyocyanin accepts electrons from ubiquinol: verified). DHODH-specific framing should be softened. Counter-evidence from NRK-52E cells exists but may be tissue-specific. |
| C2-7: Fur-PQS Functional Switch | 7.10 | **FAIL** | Individual components verified, but the feedback loop is trivially deducible from combining 2008 JBC + 2025 Nature Comms. "Functional switch" framing overstates evidence. |
| E-H8: 3-oxo-C12-HSL System Xc- | 7.00 | **FAIL** | MECHANISM IMPLAUSIBLE: SLC7A11 "hydrophobic groove" claim not supported by cryo-EM structure. 3-oxo-C12-HSL is established apoptosis inducer, not ferroptosis. |

**Passed quality gate: 1 (conditional)**
**Failed quality gate: 2**

---

## Meta-Validation

1. **For the PASS (C2-3):** Would I bet my reputation this is genuinely novel and mechanistically sound? Yes, with the caveat that "DHODH-pathway-specific" should be "ferroptosis with mitochondrial component." The individual mechanisms are verified (pyocyanin redox cycling, CoQ10H2 as DHODH substrate, pyocyanin accepting ubiquinol electrons). The gap is the combination, which is the proper domain of hypothesis generation. The NRK-52E counter-evidence is a genuine concern but in a different cell type.

2. **Search count:** C2-3: 11 searches. C2-7: 7 searches. E-H8: 7 searches. Total: 25 searches. Minimum 3 per hypothesis met.

3. **UNVERIFIABLE claims:** No core mechanism claims are unverifiable. The C2-3 DHODH-specific framing is the weakest verified claim (downgraded to "likely attacks all three axes"). E-H8's SLC7A11 binding claim is actively contradicted by structural data, not merely unverifiable.

---

## Web Search Log

All searches performed with results:

| # | Query | Key Finding |
|---|-------|-------------|
| 1 | pyocyanin ferroptosis DHODH mitochondrial lipid peroxidation | No papers found -- NOVEL |
| 2 | pyocyanin ferroptosis airway epithelial cells 2024 2025 2026 | No direct papers |
| 3 | pyocyanin CoQ10 mitochondria redox cycling superoxide | Mitochondrial redox cycling confirmed (Usher 2002) |
| 4 | DHODH CoQ10H2 ferroptosis mitochondrial defense Mao 2021 | DHODH mechanism verified |
| 5 | PQS Pseudomonas aeruginosa macrophage ferroptosis TFR1 2024 2025 | PQS-CNMT-TFR1 confirmed (Li 2025 Nat Commun) |
| 6 | pyocyanin redox cycling depletes GSH NAD lung epithelial | GSH depletion verified (O'Malley 2004) |
| 7 | Fur regulon iron excess PQS production pqsA | Iron increases PQS via kynurenine pathway |
| 8 | 3-oxo-C12-HSL SLC7A11 system Xc- cystine transport | No papers -- NOVEL |
| 9 | 3-oxo-C12-HSL ferroptosis host cell death | No ferroptosis papers; apoptosis is established mechanism |
| 10 | 3-oxo-C12-HSL GSH depletion glutathione epithelial | No GSH depletion evidence |
| 11 | SLC7A11 hydrophobic substrate binding groove lipophilic | Substrate site for amino acids, not lipophilic chains |
| 12 | 3-oxo-C12-HSL apoptosis mechanism Kravchenko 2008 | Apoptosis via mitochondrial pathway, caspases |
| 13 | pyocyanin QS regulated phzA gene expression | phz operons QS-regulated confirmed |
| 14 | Pseudomonas iron excess PQS decrease PrrF antR anthranilate | Complex: both pathways activated, net PQS increases |
| 15 | Fur iron replete PQS Pseudomonas production | Iron INCREASES PQS (Oglesby-Sherrouse 2008) |
| 16 | Pseudomonas theft-ferroptosis pLoxA | pLoxA mechanism verified (Dar 2018 JCI) |
| 17 | SLC7A11 xCT cryo-EM structure 2021 | Parker 2021 (Nat Commun) and Yan 2022 (Cell Res) |
| 18 | 3-oxo-C12-HSL lipophilic membrane acyl chain | Lipophilicity confirmed, membrane interactions known |
| 19 | erastin SLC7A11 binding structure cryo-EM | Specific pharmacophore binding (Phe254, Gln191) |
| 20 | pyocyanin concentration sputum CF micromolar | Up to 100 micromolar in CF sputum |
| 21 | Pseudomonas heme uptake iron excess Fur has operon | Phu/Has systems, Fur regulation complex |
| 22 | site:semanticscholar.org pyocyanin ferroptosis | No co-occurrence -- NOVEL |
| 23 | site:semanticscholar.org 3-oxo-C12-HSL system Xc SLC7A11 | No results |
| 24 | site:semanticscholar.org Fur PQS ferroptosis iron | No direct papers |
| 25 | pyocyanin ferroptosis contradicted OR failed | NRK-52E study: ferroptosis inhibitors didn't protect (Muller 2016) |
| 26 | 3-oxo-C12-HSL apoptosis caspase mitochondrial | Apoptosis confirmed (multiple studies, T2R14 pathway) |
| 27 | Pseudomonas iron excess Fur repress virulence | Context-dependent relationship |
| 28 | pyocyanin superoxide mitochondrial PUFA oxidation chain reaction | Superoxide/H2O2 generation confirmed |
| 29 | PQS ferroptosis pyocyanin 2025 2026 published | PQS-ferroptosis confirmed (2025); no pyocyanin-ferroptosis |
| 30 | DHODH brequinar CoQ10 mitochondrial lipid peroxidation | DHODH defense mechanism confirmed |
| 31 | pyocyanin CoQ10H2 ubiquinol oxidation depletion | No direct evidence for CoQ10H2 depletion |
| 32 | ferroptosis iron release labile iron pool Pseudomonas | Iron dynamics in P. aeruginosa infection confirmed |
| 33 | N-(3-oxododecanoyl) homoserine lactone MW structure | MW 297, C16H27NO4 |
| 34 | erastin molecular weight 3-oxo-C12-HSL comparison | Erastin 547 vs AHL 297 |
| 35 | erastin SLC7A11 binding pocket acyl chain | Specific pharmacophore interactions, not acyl chain accommodation |
| 36 | pyocyanin mitochondrial membrane potential ETC | Pyocyanin accepts electrons from ubiquinol (Guaras 2021) |
| 37 | pyocyanin cell death necrosis apoptosis ferroptosis | Apoptosis in neutrophils; paraptosis-like in NRK-52E |
